News | Radiation Therapy | August 10, 2017

First Radixact Results Presented at AAPM 2017

Studies of next-generation TomoTherapy treatment delivery system demonstrate faster planning time, high image quality and accuracy in dose calculations

First Radixact Results Presented at AAPM 2017

August 10, 2017 — Accuray Inc. announced that the first studies validating the benefits of the Radixact System were presented at the 59th Annual Meeting of the American Association of Physicists in Medicine (AAPM), held July 30-Aug. 3 in Denver. This smart radiation therapy system represents the next generation in TomoTherapy treatment delivery, significantly increasing treatment speed and ease of use, according to Accuray. The Radixact System enables clinicians to treat a wide range of cancer cases, from initial plan delivery to adaptive therapy to complex retreatments, with precision and increased efficiency.

Research highlights include:

Faster planning and reduced treatment time

A study evaluated the performance of the Radixact System based on a comparison of treatment plans developed for this system and the TomoHDA System. Treatment plans were created using the VoLO Planning Solution for the TomoHDA technology, then recreated using the Accuray Precision Treatment Planning System (TPS) for the Radixact System. Developing optimal plans using the Accuray Precision TPS was much faster, and the treatment beam-on time was reduced by up to 50 percent while maintaining the excellent plan quality. Researchers at the Miami Cancer Institute in Miami, Fla., and Accuray conducted the research.

Proven image quality and stability

The first clinical assessment of Radixact low-dose fan beam megavoltage computed tomography (MVCT) image guidance found there was no statistically significant difference in the noise, uniformity and Hounsfield units (HU) stability over the three-month evaluation period, demonstrating the strength of the system's MVCT image quality and its potential value for dose calculation. Clinicians at the Miami Cancer Institute team conducted the research.

Easy installation

Radixact and TomoTherapy System dosimetric beam characteristics were compared over a six-month period. Radixact data were within the specifications established for the TomoTherapy System and showed a good agreement with the beam model. These results indicate that the beam commissioning process will be straightforward for the Radixact System. Researchers at Miami Cancer Institute and Accuray conducted the study.

The future of radiation therapy

Two studies demonstrated the feasibility of real-time motion management leveraging the TomoTherapy System's helical delivery capabilities.

  • Accuray researchers investigated the potential for adapting the CyberKnife System's Synchrony Respiratory Tracking System to an experimental TomoTherapy System. The study showed Synchrony-like real-time respiratory motion management is technically feasible using TomoTherapy technology, enabling a high level of accuracy when delivering dose to tumors that move with respiration; and
  • The dosimetric impact of using real-time primary jaw/multileaf collimator (MLC) compensation approaches to mitigate motion during TomoHelical delivery was analyzed by a team of researchers from the University of Wisconsin-Madison and Accuray. Dose was calculated for treatment plans assuming 1) no motion, 2) respiratory motion and 3) respiratory motion compensated by adjusting the jaw and MLC position during delivery. The team found that a jaw and MLC compensation approach mitigated the large difference between planned and delivered dose caused by motion, thus enabling reductions in margin.

For more information: www.accuray.com

Related Content

Cleveland Clinic Researchers Reveal Biomarker for Guiding Prostate Cancer Treatment
News | Prostate Cancer | October 17, 2017
October 17, 2017 — Back-to-back discoveries from Cleveland Clinic demonstrate for the first time how a testosterone-r
IBA Announces First Use of Gating With Active Scanning Proton Therapy in Italy
News | Proton Therapy | October 17, 2017
October 17, 2017 — The Trento Azienda Provinciale per i Servizi Sanitari (APSS) and IBA announced the successful comp
Elekta and Brainlab Offer Streamlined Workflow for Stereotactic Radiotherapy
News | Radiation Therapy | October 16, 2017
Elekta and Brainlab have reconfirmed their alliance for the integrated use of the Elekta Versa HD linear accelerator...
Pancreatic Cancer Outcome Highlights via On-table Adaptive MR-guided Radiation Therapy, MRI guided RT.
Sponsored Content | Webinar | Radiation Therapy | October 13, 2017
The webinar "Pancreatic Cancer Outcome Highlights via On-table Adaptive MR-guided Radiation" will be presented by Par
National Breast Center Founder Names Top Three Innovations in Breast Cancer Treatment
News | Women's Health | October 11, 2017
In 2017, invasive breast cancer will be diagnosed in about 252,710 women and 2,470 men in the U.S. and remains the...
CyberKnife System Provides Excellent Long-Term Control of Low-Risk Prostate Cancer
News | Stereotactic Body Radiation Therapy (SBRT) | October 10, 2017
Accuray Inc. announced that data from a prospective study of 230 men with low-risk prostate cancer showed 98.4 percent...
News | Image Guided Radiation Therapy (IGRT) | October 10, 2017
Elekta announced that members of the Elekta MR-linac Consortium reported data related to the advancement of the company...
Sponsored Content | Videos | Radiation Therapy | October 09, 2017
David Beyer, M.D., chairman of the board for the American Society of Radiation Oncology (ASTRO), discusses the key th
Sponsored Content | Videos | Radiation Therapy | October 09, 2017
Benjamin Movsas, M.D., chair of the American Society for Radiation Oncology (ASTRO) Scientific Committee, explains ho
News | Brachytherapy Systems | October 05, 2017
External researchers presented new clinical data supporting the use of iCAD’s Xoft Axxent Electronic Brachytherapy (eBx...
Overlay Init